1 Market Overview

• 1.1 Product Overview and Scope
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Market Analysis by Type
  • 1.3.1 Overview: Global Tagolimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
  • 1.3.2 Monoclonal antibody (mAb)
  • 1.3.3 Polyclonal antibody (pAb)
  • 1.3.4 Bispecific antibody
• 1.4 Market Analysis by Specification
  • 1.4.1 Overview: Global Tagolimab Consumption Value by Specification: 2021 Versus 2025 Versus 2032
  • 1.4.2 100 mg/vial
  • 1.4.3 200 mg/vial
• 1.5 Market Analysis by Sales Channel
  • 1.5.1 Overview: Global Tagolimab Consumption Value by Sales Channel: 2021 Versus 2025 Versus 2032
  • 1.5.2 Hospital
  • 1.5.3 Retail
  • 1.5.4 Online
• 1.6 Market Analysis by Route of Administration
  • 1.6.1 Overview: Global Tagolimab Consumption Value by Route of Administration: 2021 Versus 2025 Versus 2032
  • 1.6.2 Intravenous Infusion (IV)
  • 1.6.3 Subcutaneous Injection (SC)
• 1.7 Market Analysis by Application
  • 1.7.1 Overview: Global Tagolimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
  • 1.7.2 Nasopharyngeal Carcinoma (NPC)
  • 1.7.3 Lung Cancer
  • 1.7.4 Gastric Cancer
  • 1.7.5 Others
• 1.8 Global Tagolimab Market Size & Forecast
  • 1.8.1 Global Tagolimab Consumption Value (2021 & 2025 & 2032)
  • 1.8.2 Global Tagolimab Sales Quantity (2021-2032)
  • 1.8.3 Global Tagolimab Average Price (2021-2032)

2 Manufacturers Profiles

• 2.1 Kelun-Biotech（China）
  • 2.1.1 Kelun-Biotech（China） Details
  • 2.1.2 Kelun-Biotech（China） Major Business
  • 2.1.3 Kelun-Biotech（China） Tagolimab Product and Services
  • 2.1.4 Kelun-Biotech（China） Tagolimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
  • 2.1.5 Kelun-Biotech（China） Recent Developments/Updates

3 Competitive Environment: Tagolimab by Manufacturer

• 3.1 Global Tagolimab Sales Quantity by Manufacturer (2021-2026)
• 3.2 Global Tagolimab Revenue by Manufacturer (2021-2026)
• 3.3 Global Tagolimab Average Price by Manufacturer (2021-2026)
• 3.4 Market Share Analysis (2025)
  • 3.4.1 Producer Shipments of Tagolimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
  • 3.4.2 Top 3 Tagolimab Manufacturer Market Share in 2025
  • 3.4.3 Top 6 Tagolimab Manufacturer Market Share in 2025
• 3.5 Tagolimab Market: Overall Company Footprint Analysis
  • 3.5.1 Tagolimab Market: Region Footprint
  • 3.5.2 Tagolimab Market: Company Product Type Footprint
  • 3.5.3 Tagolimab Market: Company Product Application Footprint
• 3.6 New Market Entrants and Barriers to Market Entry
• 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

• 4.1 Global Tagolimab Market Size by Region
  • 4.1.1 Global Tagolimab Sales Quantity by Region (2021-2032)
  • 4.1.2 Global Tagolimab Consumption Value by Region (2021-2032)
  • 4.1.3 Global Tagolimab Average Price by Region (2021-2032)
• 4.2 North America Tagolimab Consumption Value (2021-2032)
• 4.3 Europe Tagolimab Consumption Value (2021-2032)
• 4.4 Asia-Pacific Tagolimab Consumption Value (2021-2032)
• 4.5 South America Tagolimab Consumption Value (2021-2032)
• 4.6 Middle East & Africa Tagolimab Consumption Value (2021-2032)

5 Market Segment by Type

• 5.1 Global Tagolimab Sales Quantity by Type (2021-2032)
• 5.2 Global Tagolimab Consumption Value by Type (2021-2032)
• 5.3 Global Tagolimab Average Price by Type (2021-2032)

6 Market Segment by Application

• 6.1 Global Tagolimab Sales Quantity by Application (2021-2032)
• 6.2 Global Tagolimab Consumption Value by Application (2021-2032)
• 6.3 Global Tagolimab Average Price by Application (2021-2032)

7 North America

• 7.1 North America Tagolimab Sales Quantity by Type (2021-2032)
• 7.2 North America Tagolimab Sales Quantity by Application (2021-2032)
• 7.3 North America Tagolimab Market Size by Country
  • 7.3.1 North America Tagolimab Sales Quantity by Country (2021-2032)
  • 7.3.2 North America Tagolimab Consumption Value by Country (2021-2032)
  • 7.3.3 United States Market Size and Forecast (2021-2032)
  • 7.3.4 Canada Market Size and Forecast (2021-2032)
  • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

• 8.1 Europe Tagolimab Sales Quantity by Type (2021-2032)
• 8.2 Europe Tagolimab Sales Quantity by Application (2021-2032)
• 8.3 Europe Tagolimab Market Size by Country
  • 8.3.1 Europe Tagolimab Sales Quantity by Country (2021-2032)
  • 8.3.2 Europe Tagolimab Consumption Value by Country (2021-2032)
  • 8.3.3 Germany Market Size and Forecast (2021-2032)
  • 8.3.4 France Market Size and Forecast (2021-2032)
  • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
  • 8.3.6 Russia Market Size and Forecast (2021-2032)
  • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

• 9.1 Asia-Pacific Tagolimab Sales Quantity by Type (2021-2032)
• 9.2 Asia-Pacific Tagolimab Sales Quantity by Application (2021-2032)
• 9.3 Asia-Pacific Tagolimab Market Size by Region
  • 9.3.1 Asia-Pacific Tagolimab Sales Quantity by Region (2021-2032)
  • 9.3.2 Asia-Pacific Tagolimab Consumption Value by Region (2021-2032)
  • 9.3.3 China Market Size and Forecast (2021-2032)
  • 9.3.4 Japan Market Size and Forecast (2021-2032)
  • 9.3.5 South Korea Market Size and Forecast (2021-2032)
  • 9.3.6 India Market Size and Forecast (2021-2032)
  • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
  • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

• 10.1 South America Tagolimab Sales Quantity by Type (2021-2032)
• 10.2 South America Tagolimab Sales Quantity by Application (2021-2032)
• 10.3 South America Tagolimab Market Size by Country
  • 10.3.1 South America Tagolimab Sales Quantity by Country (2021-2032)
  • 10.3.2 South America Tagolimab Consumption Value by Country (2021-2032)
  • 10.3.3 Brazil Market Size and Forecast (2021-2032)
  • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

• 11.1 Middle East & Africa Tagolimab Sales Quantity by Type (2021-2032)
• 11.2 Middle East & Africa Tagolimab Sales Quantity by Application (2021-2032)
• 11.3 Middle East & Africa Tagolimab Market Size by Country
  • 11.3.1 Middle East & Africa Tagolimab Sales Quantity by Country (2021-2032)
  • 11.3.2 Middle East & Africa Tagolimab Consumption Value by Country (2021-2032)
  • 11.3.3 Turkey Market Size and Forecast (2021-2032)
  • 11.3.4 Egypt Market Size and Forecast (2021-2032)
  • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
  • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

• 12.1 Tagolimab Market Drivers
• 12.2 Tagolimab Market Restraints
• 12.3 Tagolimab Trends Analysis
• 12.4 Porters Five Forces Analysis
  • 12.4.1 Threat of New Entrants
  • 12.4.2 Bargaining Power of Suppliers
  • 12.4.3 Bargaining Power of Buyers
  • 12.4.4 Threat of Substitutes
  • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

• 13.1 Raw Material of Tagolimab and Key Manufacturers
• 13.2 Manufacturing Costs Percentage of Tagolimab
• 13.3 Tagolimab Production Process
• 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

• 14.1 Sales Channel
  • 14.1.1 Direct to End-User
  • 14.1.2 Distributors
• 14.2 Tagolimab Typical Distributors
• 14.3 Tagolimab Typical Customers

15 Research Findings and Conclusion

16 Appendix

• 16.1 Methodology
• 16.2 Research Process and Data Source

According to our (Global Info Research) latest study, the global Tagolimab market size was valued at US$ 45.69 million in 2025 and is forecast to a readjusted size of US$ 649 million by 2032 with a CAGR of 24.4% during review period.
Tagolimab is a monoclonal antibody currently in the clinical development stage, primarily used in the field of cancer immunotherapy. It exerts its anti-tumor effects by specifically targeting tumor-associated antigens or immune regulatory pathways, thereby modulating the immune system’s ability to recognize and eliminate tumor cells. As a new generation of targeted biologic therapy, Tagolimab has shown potential applications in the treatment of various solid tumors and hematologic malignancies, particularly in improving response rates to immunotherapy and overcoming tumor immune evasion. At present, the drug remains under clinical investigation, and its safety and efficacy are still being further evaluated.In 2025, global tagitanlimab production reached approximately 100,000 vials
Tagolimab, as a monoclonal antibody currently in the clinical development stage, is positioned within the rapidly growing cancer immunotherapy market and demonstrates considerable market potential. In recent years, driven by the rising incidence of cancer, advancements in precision medicine, and continuous breakthroughs in immunotherapy technologies, the global cancer immunotherapy market has maintained strong growth, with antibody drugs such as PD-1/PD-L1 inhibitors reaching a scale of tens of billions of dollars. In this context, if Tagolimab demonstrates favorable safety and efficacy in clinical trials and successfully obtains regulatory approval, it is expected to capture a certain share in niche indication markets. However, as it has not yet been commercialized, its market size will remain limited in the short term, and it will also face competitive pressure from established marketed products. Therefore, its future market performance will largely depend on clinical progress, differentiated advantages, and commercialization capabilities.
This report is a detailed and comprehensive analysis for global Tagolimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tagolimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tagolimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tagolimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Tagolimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tagolimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tagolimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Kelun-Biotech（China）, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tagolimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Monoclonal antibody (mAb)
Polyclonal antibody (pAb)
Bispecific antibody
Market segment by Specification
100 mg/vial
200 mg/vial
Market segment by Sales Channel
Hospital
Retail
Online
Market segment by Route of Administration
Intravenous Infusion (IV)
Subcutaneous Injection (SC)
Market segment by Application
Nasopharyngeal Carcinoma (NPC)
Lung Cancer
Gastric Cancer
Others
Major players covered
Kelun-Biotech（China）
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tagolimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tagolimab, with price, sales quantity, revenue, and global market share of Tagolimab from 2021 to 2026.
Chapter 3, the Tagolimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tagolimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tagolimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tagolimab.
Chapter 14 and 15, to describe Tagolimab sales channel, distributors, customers, research findings and conclusion.